secwatch.observer — SEC 8-K summary
======================================

Issuer:     Zentalis Pharmaceuticals, Inc. (ZNTL)
CIK:        0001725160
Form:       8-K
Filed at:   2025-11-10T23:59:59+00:00
Accession:  0001725160-25-000159
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Zentalis Q3 cash $280.7M, cuts R&D spend 37% YoY; DENALI trial on track for data by YE2026
--------------------------------------------------------------------------------

- Cash and marketable securities $280.7M as of Sep 30, 2025; runway into late 2027.
- R&D expenses $23.0M in Q3 2025, down 37.5% from $36.8M in Q3 2024.
- G&A expenses $10.8M, down 26% from $14.6M YoY.
- Phase 2 DENALI trial of azenosertib in Cyclin E1-positive PROC on track; topline data expected by year end 2026, potentially supporting accelerated approval.
- TETON Phase 2 in USC completed enrollment; further development limited to partnering or capital allocation.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1725160/000172516025000159/0001725160-25-000159-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1725160/000172516025000159/zntl-20251110.htm
  HTML page:      https://secwatch.observer/filing/0001725160-25-000159

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer